Stock Events

Stock Events

ImageneBio 

$6.09
0
+$0.18+3.05% 15:20 Today

Statistics

Day High
6.09
Day Low
5.83
52W High
18
52W Low
3.94
Volume
12,292
Avg. Volume
-
Mkt Cap
68.69M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

7AugExpected
Q2 2025
Q3 2025
Q1 2026
Next
-2.91
-2.05
-1.19
-0.33
Expected EPS
-0.976667
Actual EPS
N/A

Financials

-6,549.38%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
800,000Revenue
-52.4MNet Income

Analyst Ratings

2.00Average Price Target
The highest estimate is 2.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
0%
Hold
0%
Sell
100%

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Array Technologies
ARRY
Mkt Cap979.87M
Array BioPharma is involved in the development of drugs for cancer, competing in the same therapeutic area as Ikena Oncology.
Agios Pharmaceuticals
AGIO
Mkt Cap2.22B
Agios Pharmaceuticals works on metabolic immuno-oncology, which competes with Ikena's cancer metabolism programs.
Incyte
INCY
Mkt Cap23.32B
Incyte Corporation has a broad portfolio in oncology, including targeted therapies, making it a direct competitor.
Kura Oncology
KURA
Mkt Cap985.4M
Kura Oncology focuses on precision medicine in oncology, directly competing with Ikena's approach to cancer treatment.
Xencor
XNCR
Mkt Cap1.16B
Xencor is involved in engineering monoclonal antibodies for the treatment of cancer, competing in the biologics space with Ikena.
Fate Therapeutics
FATE
Mkt Cap361.33M
Fate Therapeutics is working on programmed cellular immunotherapies for cancer, offering competitive alternatives to Ikena's treatments.
Novartis
NVS
Mkt Cap293.94B
Novartis is a large pharmaceutical company with a significant oncology division, competing across a broad range of cancer therapies including areas Ikena Oncology targets.

About

ImageneBio Inc (IMA) is a biotechnology company with therapies currently undergoing human trials. The firm concentrates on creating innovative medical treatments for a variety of immune-related and inflammatory diseases. A key component of their pipeline is IMG-007, a non-depleting anti-OX40 monoclonal antibody, which is now in Phase 2b clinical studies targeting atopic dermatitis.
Show more...
CEO
Dr. Kristin Yarema Ph.D.
Employees
17
Country
United States
ISIN
US45175G2075

Listings

XNAS
US
IMA
BOATS
BOATS
IMA.BOATS

0 Comments

Share your thoughts

FAQ

What is ImageneBio stock price today?▼
The current price of IMA is $6.09 USD — it has increased by +3.05% in the past 24 hours. Watch ImageneBio stock price performance more closely on the chart.
What is ImageneBio stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange ImageneBio stocks are traded under the ticker IMA.
What is ImageneBio market cap?▼
Today ImageneBio has the market capitalization of 68.69M
When is the next ImageneBio earnings date?▼
ImageneBio is going to release the next earnings report on August 07, 2026.
What were ImageneBio earnings last quarter?▼
IMA earnings for the last quarter are -0.95 USD per share, whereas the estimation was -0.67 USD resulting in a -42.5% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is ImageneBio revenue for the last year?▼
ImageneBio revenue for the last year amounts to 800,000 USD.
What is ImageneBio net income for the last year?▼
IMA net income for the last year is -52.4M USD.
How many employees does ImageneBio have?▼
As of July 13, 2026, the company has 17 employees.
In which sector is ImageneBio located?▼
ImageneBio operates in the Health & Wellness sector.
When did ImageneBio complete a stock split?▼
The last stock split for ImageneBio was on July 24, 2025 with a ratio of 1:1.
Where is ImageneBio headquartered?▼
ImageneBio is headquartered in San Diego, United States.